AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
RegulatoryapprovedRINVOQPositive
AI Analysis
Summary
AbbVie announced European Commission approval of RINVOQ (upadacitinib) for non-segmental vitiligo in adults and adolescents, making it the first and only systemic medication approved in the EU for this indication, supported by positive Phase 3 Viti-Up trial data.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
European Commission approval for treatment of non-segmental vitiligo in adults and adolescents
Importance:8/10
Sentiment:
0.95
regulatory approvalEuropean Commissiondermatologyfirst-in-classsystemic therapy
Related Companies
Read the original article
Published by PR Newswire Biotech on July 29, 2026 7:00 AM